Magné N, Chargari C, Conforti R, Toillon R-A, Bauduceau O, Védrine L, Khayat D, Spano J-P
Service d'oncologie médicale, hôpital Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
Bull Cancer. 2010 Mar;97(3):385-95. doi: 10.1684/bdc.2010.1051.
The importance of targeted therapies has been emphasized by clinical trials using antiangiogenic or HER2 inhibitors in breast cancer. First with trastuzumab, it was demonstrated that targeted therapies may improve outcome in patients with HER overexpressing breast cancer in metastatic or adjuvant settings. The emerging role for angiogenesis inhibitors has also been demonstrated with bevacizumab. Unfortunately, there is growing clinical and biological evidence that tumour cells may develop unexpected and complex mechanisms of resistance to those targeted therapies. This review outlines the mechanisms by which tumour cells may resist to new targeted agents. Most recent developments are also highlighted.
在乳腺癌中使用抗血管生成或HER2抑制剂的临床试验强调了靶向治疗的重要性。首先是曲妥珠单抗，它证明了靶向治疗可改善HER过表达乳腺癌患者在转移或辅助治疗中的预后。贝伐单抗也证明了血管生成抑制剂的新作用。不幸的是，越来越多的临床和生物学证据表明，肿瘤细胞可能对这些靶向治疗产生意想不到的复杂耐药机制。这篇综述概述了肿瘤细胞可能对新型靶向药物产生耐药的机制。还强调了最新进展。
